|
KYTX Kyverna Therapeutics Inc 1994702 |
| Income Statement |
|
Net Income
|
2026-03-31
|
$-39,728,000.00 |
| Balance Sheet |
|
Current Assets
|
$241,726,000.00 |
|
Assets
|
$257,024,000.00 |
|
Current Liabilities
|
$29,674,000.00 |
|
Liabilities
|
$61,444,000.00 |
|
Equity
|
$195,580,000.00 |
|
Shares Out
|
60532500.00 |
| Cash Flow Statement |
|
Operating Cash Flow
|
$-41,597,000.00 |
|
Investing Cash Flow
|
$-50,201,000.00 |
| Market Analysis |
Market Cap
|
$453,388,425.00 |
|
Price
|
$7.28 |
|
BVPS
|
3.23 |
|
PB
|
2.32 |
|
EPS
|
-0.66 |
|
FCF
|
$-41,602,000.00 |
|
| Dividends |
|
Dividend Data Last Updated
|
2026-08-01 09:31:29 |
|
|
| Earnings |
|
Earnings Last Updated
|
2026-08-03 10:01:25 |
|
| Apr |
May |
Jun |
| 2026-03-26 |
-0.80 |
|
|
2026-05-12 |
-0.66 |
|
| Jul |
Aug |
Sep |
|
|
|
|
2025-08-12 |
-0.97 |
|
| Oct |
Nov |
Dec |
|
|
|
|
2025-11-12 |
-0.85 |
|
|
Find a discrepancy? The most accurate way to find company fundamental data is to view KYTX documents filed with the SEC.
KYTX Filings
Clear
